Endur

Endur is a biotechnology company dedicated to transforming the treatment of chronic diseases through its proprietary long-acting injectable platform. The company's technology enables the sustained release of a wide range of therapeutic agents, including small molecules and complex biologics, for periods extending several months. Currently, Endur is prioritizing applications in ophthalmology to address the high treatment burden associated with conditions like wet age-related macular degeneration and diabetic retinopathy. By reducing injection frequency, the company aims to enhance patient adherence and preserve vision more effectively. The platform is designed to be compatible with existing clinical workflows and standard-of-care drugs.